Pacific EdgeASX:PEB -4.00%42 Current Ratio is 2.02 as of Mar. 2026, which is 75% below its 10-year median of 8.18. GuruFocus rates ASX:PEB with a GF Score™ of 42/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, Pacific Edge ranks better than 50.23% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Pacific Edge's current ratio for the quarter that ended in Mar. 2026 was 2.02.
Pacific Edge has a current ratio of 2.02. It generally indicates good short-term financial strength.
The historical rank and industry rank for Pacific Edge's Current Ratio or its related term are showing as below:
ASX:PEB'
s Current Ratio Range Over the Past 10 Years
Min: 2.02 Med: 8.18 Max: 18.43
Current: 2.02
During the past 13 years, Pacific Edge's highest Current Ratio was 18.43. The lowest was 2.02. And the median was 8.18.
ASX:PEB's Current Ratio is ranked better than 50.23% of 215
companies
in the Medical Diagnostics & Research industry
Industry Median: 1.96
vs ASX:PEB: 2.02
Pacific Edge (ASX:PEB) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Pacific Edge Current Ratio Related Terms
Pacific Edge Current Ratio Historical Data
* Premium members only.
The historical data trend for Pacific Edge's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PEB vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Pacific Edge's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Edge Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Current Ratio distribution charts can be found below:
* The bar in red indicates where Pacific Edge's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Edge (ASX:PEB) has a Current Ratio of 2.02 as of Mar. 2026. This is 75% below median its historical median of 8.18. Over the past decade, Pacific Edge's Current Ratio has ranged from 2.02 to 18.43. According to the industry distribution chart, Pacific Edge ranks #107 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 49.8%.
Is Pacific Edge's Current Ratio too high?
Pacific Edge's current Current Ratio of 2.02 is 75% below median its 10-year median of 8.18. Over the past 10 years, this metric has ranged from a low of 2.02 to a high of 18.43. The Medical Diagnostics & Research industry median Current Ratio is 1.96. Pacific Edge's value of 2.02 is 3.1% above this industry median. Based on the distribution chart, Pacific Edge ranks #107 out of 215 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Pacific Edge has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #107 out of 215 companies for Current Ratio. This puts Pacific Edge in the upper half of its industry. The industry median Current Ratio is 1.96. Pacific Edge's value of 2.02 is 3.1% above this benchmark. Historically, Pacific Edge's own Current Ratio has ranged from 2.02 to 18.43 over the past decade. While the company's 10-year median is 8.18 vs. the industry median of 1.96, Pacific Edge has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 1.96, based on 215 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Edge's current Current Ratio of 2.02 is 3.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 1.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Edge's current Current Ratio is 2.02, which is 75% below median its own 10-year median of 8.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.24 — trading 380% above its estimated fair value. The current Current Ratio is 2.02, which is 75% below median its 10-year median of 8.18 and 3.1% above the Medical Diagnostics & Research industry median of 1.96. Pacific Edge's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Current Ratio is 2.02 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Edge (ASX:PEB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued.
The current stock price of A$0.24 is trading 380% above its estimated GF Value™ of A$0.05.
GuruFocus considers Pacific Edge to be Significantly Overvalued.
Key valuation signals for ASX:PEB:
Current Ratio: 2.02 (75% below median its 10-year median of 8.18)
GF Value™: A$0.05 vs. price of A$0.24 (380% above fair value)
Industry Position: 3.1% above the Medical Diagnostics & Research median (#107 of 215)
No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
42GF Score
Get the complete analysis for ASX:PEB
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PEB has been successfully added to your 
